Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
The price of Genmab ADR (NASDAQ: GMAB) closed at $29.07 in the last session, up 0.80% from day before closing price of $28.84. In other words, the price has increased by $0.80 from its previous closing price. On the day, 1.04 million shares were traded. GMAB stock price reached its highest trading level at $29.115 during the session, while it also had its lowest trading level at $28.74.
Ratios:
We take a closer look at GMAB’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 6.17 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 17.79. For the most recent quarter (mrq), Quick Ratio is recorded 6.20 and its Current Ratio is at 6.22. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.02.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jun 17 ’25 when Klimovsky Judith V bought 1,300 shares for $51.69 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GMAB now has a Market Capitalization of 17893928960 and an Enterprise Value of -963121536. As of this moment, Genmab’s Price-to-Earnings (P/E) ratio for their current fiscal year is 14.51, and their Forward P/E ratio for the next fiscal year is 14.91. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.20. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.28 while its Price-to-Book (P/B) ratio in mrq is 3.37. Its current Enterprise Value per Revenue stands at -0.264 whereas that against EBITDA is -0.726.
Stock Price History:
The Beta on a monthly basis for GMAB is 0.96, which has changed by 0.19237077 over the last 52 weeks, in comparison to a change of 0.1529237 over the same period for the S&P500. Over the past 52 weeks, GMAB has reached a high of $29.51, while it has fallen to a 52-week low of $17.24. The 50-Day Moving Average of the stock is 16.75%, while the 200-Day Moving Average is calculated to be 33.28%.
Shares Statistics:
According to the various share statistics, GMAB traded on average about 1.26M shares per day over the past 3-months and 1339720 shares per day over the past 10 days. Insiders hold about 0.00% of the company’s shares, while institutions hold 10.46% stake in the company. Shares short for GMAB as of 1757894400 were 3494733 with a Short Ratio of 2.77, compared to 1755216000 on 3413784. Therefore, it implies a Short% of Shares Outstanding of 3494733 and a Short% of Float of 0.5700000000000001.
Earnings Estimates
Its stock is currently analyzed by 3.0 different market analysts. The consensus estimate for the next quarter is $0.4, with high estimates of $0.53 and low estimates of $0.25.
Analysts are recommending an EPS of between $1.79 and $1.53 for the fiscal current year, implying an average EPS of $1.68. EPS for the following year is $1.76, with 4.0 analysts recommending between $1.99 and $1.42.
Revenue Estimates
According to 9 analysts, . The current quarter’s revenue is expected to be $6.23B. It ranges from a high estimate of $6.51B to a low estimate of $5.95B. As of . The current estimate, Genmab ADR’s year-ago sales were $5.54BFor the next quarter, 9 analysts are estimating revenue of $6.62B. There is a high estimate of $7.35B for the next quarter, whereas the lowest estimate is $6.23B.
A total of 19 analysts have provided revenue estimates for GMAB’s current fiscal year. The highest revenue estimate was $25.25B, while the lowest revenue estimate was $22.73B, resulting in an average revenue estimate of $23.47B. In the same quarter a year ago, actual revenue was $21.53BBased on 19 analysts’ estimates, the company’s revenue will be $27.04B in the next fiscal year. The high estimate is $29.42B and the low estimate is $23.32B.
